Method for evaluation of presence of or risk of colon tumors

A method of detecting the presence or absence of an adenoma or polyp of the colon in a subject, wherein said subject has no symptoms or family history of adenoma or polyps of the colon, said method comprising the steps of:

• (a) obtaining a biological sample from said subject;
• (b) performing an analysis of the biological sample for the presence and amount of one or more proteins and/or peptides;
• (c) comparing the presence and amount of one or more proteins and/or peptides from said biological sample to a control reference value;
• and
• (d) correlating the presence and amount of one or more proteins and/or peptides with the subject's adenoma or polyp status.

A method of detecting the presence or absence of an adenoma or polyp of the colon in a subject in whom a colonoscopy yielded a negative result comprising the steps of:

• (a) obtaining a biological sample from a subject with a negative diagnosis of adenoma or polyps based on colonoscopy;
• (b) performing an analysis of the biological sample for the presence and amount of one or more proteins and/or peptides;
• (c) comparing the presence and amount of one or more proteins and/or peptides from said biological sample to a control reference value;
• and
• (d) correlating the presence and amount of one or more proteins and/or peptides with the subject's adenoma or polyp status.

A method of detecting recurrence or absence of an adenoma or polyp of the colon in a subject previously treated for adenoma or polyps of the colon comprising the steps of:

• (a) obtaining a biological sample from a subject previously treated for adenoma or polyps of the colon;
• (b) performing an analysis of the biological sample for the presence and amount of one or more proteins and/or peptides;
• (c) comparing the presence and amount of one or more proteins and/or peptides from said biological sample to a control reference value;
• and
• (d) correlating the presence and amount of one or more proteins and/or peptides with the subject's adenoma or polyp status.

A method of protein and/or peptide detection for diagnostic application comprising the steps of:

• (a) obtaining a biological sample from a subject;
• (b) performing an analysis of the biological sample for the presence and amount of one or more proteins and/or peptides;
• (c) comparing the presence and amount of one or more proteins and/or peptides from said biological sample to a control reference value;
• and
• (d) correlating the presence and amount of one or more proteins and/or peptides with a diagnosis for said subject;
• wherein said analysis detects the presence and amount of one or more of the following sets:
• i) one or more proteins selected from SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, and/or the proteins in FIG. 9 and combinations thereof;
• ii) one or more peptide fragments of SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), and ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, and/or the proteins in FIG. 9 combinations thereof;
• iii) one or more peptides with a sequence homology to SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, and/or the proteins in FIG. 9 and combinations thereof, wherein said sequence homology is selected from the group of greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, and greater than 99%;
• iv) one or more binding partners of SCDC26 (CD26), CEA molecule 5 (CEACAM5), CA195 (CCR5), CA19-9, M2PK (PKM2), TIMP1, P-selectin (SELPLG), VEGFA, HcGB (CGB), VILLIN, TATI (SPINK1), A-L-fucosidase (FUCA2), and ANXA5, GAPDH, PKM2, ANXA4, GARS, RRBP1, KRT8, SYNCRIP, S100A9, ANXA3, CAPG, HNRNPF, PPA1, NME1, PSME3, AHCY, TPT1, HSPB1, and RPSA, and/or the proteins in FIG. 9 combinations thereof;
• and
• v) a protein or peptide from which one or more neutral mass clusters from FIG. 7 or FIG. 8 is derived.

A method for the diagnosis, prediction, prognosis and/or monitoring a colon disease in a subject comprising:

• measuring at least one biomarker selected from the group ACTB ACTH, ANGT, SAHH, ALDR, AKT1, ALBU, AL1A1, AL1B1, ALDOA, AMY2B, ANXA1, ANXA3, ANXA4, ANXA5, APC, APOA1, APOC1, APOH, GDIR1, ATPB, BANK1, MIC1, CA195, CO3, CO9, CAH1, CAH2, CALR, CAPG, CD24, CD63, CDD, CEAM3, CEAM5, CEAM6 CGHB, CH3L1, KCRB, CLC4D, CLUS, CNN1, COR1C, CRP, CSF1, CTNB1, CATD, CATS, CATZ, CUL1, SYDC, DEF1, DEF3, DESM, DPP4, DPYL2, DYHC1, ECH1, EF2, IF4A3, ENOA EZRI, NIBL2, SEPR, FBX4, FIBB, FIBG, FHL1, FLNA, FRMD3, FRIH, FRIL, FUCO, GBRA1, G3P, SYG, GDF15, GELS, GSTP1, HABP2, HGF, 1A68, HMGB1, ROA1, ROA2, HNRPF, HPT, HS90B, ENPL, GRP75, HSPB1, CH60, SIAL, IFT74, IGF1, IGHA2, IL2RB, IL8, IL9, RASK, K1C19, K2C8, LAMA2, LEGS, LMNB1, MARE1, MCM4, MIF, MMP7, MMP9, CD20, MYL6, MYL9, NDKA, NNMT, A1AG1, PCKGM, PDIA3, PDIA6, PDXK, PEBP1, PIPNA, KPYM, UROK, IPYR, PRDX1, KPCD1, PRL, TMG4, PSME3, PTEN, FAK1, FAK2, RBX1, REG4, RHOA, RHOB, RHOC, RSSA, RRBP1, S10AB, S10AC, S10A8, S109, SAA1, SAA2, SEGN, SDCG3, DHSA, SBP1, SELPL, SEP9, A1AT, AACT, ILEU, SPB6, SF3B3, SKP1, ADT2, ISK1, SPON2, OSTP, SRC, STK11, HNRPQ, TAL1, TRFE, TSP1, TIMP1, TKT, TSG6, TR10B, TNF6B, P53, TPM2, TCTP, TRAP1, THTR, TBB1, UGDH, UGPA, VEGFA, VILI, VIME, VNN1, 1433Z, CCR5, FUCO, and combinations thereof in a biological sample from the subject.